Equities research analysts expect Mediwound Ltd (NASDAQ:MDWD) to report $1.10 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Mediwound’s earnings. The highest sales estimate is $1.20 million and the lowest is $1.00 million. Mediwound posted sales of $1.03 million in the same quarter last year, which suggests a positive year-over-year growth rate of 6.8%. The company is expected to report its next quarterly earnings results on Tuesday, August 6th.
On average, analysts expect that Mediwound will report full-year sales of $8.52 million for the current year, with estimates ranging from $7.80 million to $8.96 million. For the next financial year, analysts anticipate that the company will post sales of $16.22 million, with estimates ranging from $13.80 million to $18.20 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Mediwound.
Mediwound (NASDAQ:MDWD) last posted its quarterly earnings results on Tuesday, May 21st. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). Mediwound had a negative net margin of 18.43% and a negative return on equity of 383.19%. The business had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.60 million.
MDWD opened at $2.59 on Friday. Mediwound has a 1-year low of $2.57 and a 1-year high of $6.75. The firm has a fifty day simple moving average of $3.39. The company has a current ratio of 3.99, a quick ratio of 3.79 and a debt-to-equity ratio of 0.40. The company has a market cap of $81.54 million, a PE ratio of -5.29 and a beta of 0.57.
A number of hedge funds have recently bought and sold shares of the business. Oppenheimer & Co. Inc. increased its position in Mediwound by 6.5% during the 1st quarter. Oppenheimer & Co. Inc. now owns 32,800 shares of the biopharmaceutical company’s stock worth $164,000 after buying an additional 2,000 shares during the period. Meitav Dash Investments Ltd. increased its position in Mediwound by 0.6% during the 1st quarter. Meitav Dash Investments Ltd. now owns 598,508 shares of the biopharmaceutical company’s stock worth $2,993,000 after buying an additional 3,536 shares during the period. Deutsche Bank AG increased its position in Mediwound by 73.5% during the 4th quarter. Deutsche Bank AG now owns 39,740 shares of the biopharmaceutical company’s stock worth $161,000 after buying an additional 16,840 shares during the period. Millennium Management LLC increased its position in Mediwound by 33.2% during the 4th quarter. Millennium Management LLC now owns 68,365 shares of the biopharmaceutical company’s stock worth $278,000 after buying an additional 17,048 shares during the period. Finally, Marshall Wace LLP bought a new position in Mediwound during the 1st quarter worth $93,000. Hedge funds and other institutional investors own 30.78% of the company’s stock.
Mediwound Company Profile
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Recommended Story: Trading Ex-Dividend
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.